Incretin Atlas › Trials › STEP UP
STEP UP
Semaglutide · obesity
Design
- Molecule(s)
- Semaglutide
- Population
- obesity
- Official title
- A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2023-01 → 2024-10
- Participants
- 1407
- Duration
- 72 weeks
- Registry
- NCT05646706
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| semaglutide 7.2 mg | obesity | 72 | 1407 | −20.7 % vs −2.4 % Δ −18.3 pp | −18.7 % vs −3.9 % Δ −14.8 pp | −0.3 vs −0.0 | 5.4 vs 1.0 | 11.6 vs 29.4 | — | — | 6.8 vs 5.5 | −9.9 vs −4.4 | verified |
| semaglutide 2.4 mg | obesity | 72 | 1407 | −17.5 % vs −2.4 % Δ −15.1 pp | −15.6 % vs −3.9 % Δ −11.7 pp | −0.3 vs −0.0 | 4.0 vs 1.0 | 11.9 vs 29.4 | — | — | 10.9 vs 5.5 | −8.7 vs −4.4 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (12)
- semaglutide 7.2 mg · weight_eff · Results, paragraph 3; Figure 2B
Using the trial product estimand, the mean change in bodyweight was –20·7% (SE 0·3) with semaglutide 7·2 mg
- semaglutide 7.2 mg · weight_tp · Table 2
–18·7% (0·4); n=950
- semaglutide 7.2 mg · ae_dc · Results, safety paragraphs; Table 3
Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg
- semaglutide 7.2 mg · disc_any · Figure 1
117 discontinued treatment
- semaglutide 7.2 mg · sae · Results; Table 3
Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg
- semaglutide 7.2 mg · hba1c · Table 2
–0·32 (0·01); n=938
- semaglutide 7.2 mg · sbp · Table 2
–9·9 (0·4); n=949
- semaglutide 2.4 mg · ae_dc · Results, Safety (text) + Table 3; safety set N=1004/201/201
Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg, eight (4·0%) of 201 receiving semaglutide 2·4 mg, and two (1·0%) of 201 receiving placebo
- semaglutide 2.4 mg · disc_any · Figure 1 trial profile
24 discontinued treatment 8 adverse events
- semaglutide 2.4 mg · sae · Results, Safety (text) + Table 3; safety set N=1004/201/201
Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg, 22 (10·9%) of 201 receiving semaglutide 2·4 mg, and 11 (5·5%) of 201 receiving placebo
- semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
HbA1c, percentage points –0·32 (0·01); n=938 –0·30 (0·02); n=186 –0·02 (0·03); n=167
- semaglutide 2.4 mg · sbp · Table 2 (supportive secondary, Blood pressure)
Systolic –9·9 (0·4); n=949 –8·7 (1·0); n=188 –4·4 (0·8); n=171
Primary sources
- Novo Nordisk A/S. Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity (STEP UP). ClinicalTrials.gov identifier NCT05646706. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05646706
- Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PMID: 40961952.
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP UP. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-up/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.